2020-12-02

Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US

Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.

Read the full press release: https://www.camurus.com/

Latest news

2019-02-08

60 years of driving innovation in Skåne

In 1959, Gunnar Sandberg established ElektroSandberg and lay the foundation for what we now know as Sandberg Develop…

Read more

2019-02-06

Camurus' Full year report 2018

Camurus' has published their Full year report 2018.

Read more

2019-01-14

Spin-off of Solo Rescue from GRANULDISK

During the summer it was decided to spin off operations focused on the decontamination of fire rescue equipment from…

Read more

2019-01-14

New CEO at GRANULDISK

As of January 7 Mikael Samuelsson is the new CEO for GRANULDISK.

Read more

2019-01-07

New CEO at SWATAB

In November 2019 Mats Marklund took office as CEO for SWATAB.

Read more